Overview
LCTX market data
Price History
LCTX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.28 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.54 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -263.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.97 – $2.09 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $269.3M · P/B 8.63 · P/S 19.32.
Company News
8-K filing — Lineage Cell Therapeutics, Inc. (LCTX)SEC EDGAR · Aug 6, 2026, 8:11 PM
Lineage Cell Therapeutics Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $1.069M Miss $1.531M EstimateBenzinga · Aug 6, 2026, 8:02 PM
Lineage Cell Therapeutics Updates COR1 Corneal Cell Transplant Program; Highlights Scalable Allogeneic Production Via AlloSCOPE Platform And Plans Conference Call TodayBenzinga · Jul 13, 2026, 12:08 PM
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative MarketsBenzinga · May 20, 2026, 2:15 PM